The ANP story is getting more compelling every day. The last time Pfizer failed with their gene therapy trials we saw a major rerate in the ANP share price. Billions of dollars invested in GT and now the future is looking bleak and the FDA being risk averse will be extremely cautious of approving any future GT research proposals. In steps ANP with a positive data for inflammation and fibrosis. We can no longer be ignored. I expect Insto's to be all over this in the next couple weeks.... so exciting, GLTA holders..
Where others have failed will Atl1102 succeed ?, page-385
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.8¢ |
Change
-0.003(3.70%) |
Mkt cap ! $82.67M | |||
| Open | High | Low | Value | Volume |
| 8.1¢ | 8.1¢ | 7.8¢ | $215.5K | 2.715M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 137820 | 7.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.0¢ | 319232 | 3 |
View Market Depth
| Last trade - 15.59pm 19/11/2024 (20 minute delay) ? |
| PER (ASX) Chart |